Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!

Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.

Ron Price Biography and Net Worth

Insider of Accelerate Diagnostics

Ron Price has served as Chief Commercial Officer, Americas since April of 2015. Mr. Price has over 20 years of commercial operations experience and a proven track record of leading sales and marketing teams to achieve double-digit revenue growth and strong bottom-line performance. Prior to joining the company, Mr. Price served as Vice President, Commercial Operations for Roche Point of Care managing all commercial responsibilities across three separate product lifecycles. In addition, Ron held a number of sales, marketing, and leadership roles with Ventana Medical Systems from 2001 to 2012 following 5 years at Bayer Healthcare Diagnostics. Mr. Price holds a B.S. in Clinical Laboratory Sciences, Cytology from the University of Oklahoma.

What is Ron Price's net worth?: The estimated net worth of Ron Price is at least $3,776.73 as of April 22nd, 2022. Mr. Price owns 4,061 shares of Accelerate Diagnostics stock worth more than $3,777 as of April 26th. This net worth evaluation does not reflect any other assets that Mr. Price may own. Learn More about Ron Price's net worth.
How do I contact Ron Price?: The corporate mailing address for Mr. Price and other Accelerate Diagnostics executives is 3950 South Country Club Suite 470, Tucson AZ, 85714. Accelerate Diagnostics can also be reached via phone at (520) 365-3100 and via email at [email protected]. Learn More on Ron Price's contact information.
Has Ron Price been buying or selling shares of Accelerate Diagnostics?: Ron Price has not been actively trading shares of Accelerate Diagnostics during the past quarter. Most recently, Ron Price sold 1,507 shares of the business's stock in a transaction on Friday, April 22nd. The shares were sold at an average price of $9.80, for a transaction totalling $14,768.60. Following the completion of the sale, the insider now directly owns 4,061 shares of the company's stock, valued at $39,797.80. Learn More on Ron Price's trading history.
Who are Accelerate Diagnostics' active insiders?: Accelerate Diagnostics' insider roster includes Hany Massarany (Director), Jack Phillips (CEO), Ron Price (Insider), Steven Reichling (CFO), and Jack Schuler (Director). Learn More on Accelerate Diagnostics' active insiders.
Are insiders buying or selling shares of Accelerate Diagnostics?: During the last twelve months, insiders at the medical research company sold shares 24 times. They sold a total of 107,388 shares worth more than $145,458.61. The most recent insider tranaction occured on April, 17th when CEO Jack Phillips sold 26,735 shares worth more than $20,853.30. Insiders at Accelerate Diagnostics own 43.6% of the company. Learn More about insider trades at Accelerate Diagnostics.
Information on this page was last updated on 4/17/2024.

Ron Price Insider Trading History at Accelerate Diagnostics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/22/2022	Sell	1,507	$9.80	$14,768.60	4,061
5/13/2021	Sell	628	$67.60	$42,452.80	2,120

Ron Price Buying and Selling Activity at Accelerate Diagnostics

Accelerate Diagnostics Company Overview

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. The company was incorporated in 1982 and is headquartered in Tucson, Arizona.

Today's Range

Now: $0.93

$0.89

$0.95

50 Day Range

MA: $0.97

$0.74

$1.19

2 Week Range

Now: $0.93

$0.73

$11.90

Volume

1,704 shs

Average Volume

113,241 shs

Market Capitalization

$20.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.52

Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!

From Priority Gold | Ad